Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jbo.2015.11.001 http://scihub22266oqcxt.onion/10.1016/j.jbo.2015.11.001 C4782017!4782017!26998420     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Bone+Oncol 2016 ; 5 (1): 1-4 Nephropedia Template TP {{tp|p=26998420|t=2016. Ibandronate: The loading dose concept in the treatment of metastatic bone pain |pdf=|usr=}}{{26998420}} gab.com Text Ibandronate: The loading dose concept in the treatment of metastatic bone pain JO: J Bone Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26998420 #FOAvip Background/Aim: Severe bone pain is experienced by 60?80% of patients with metastatic bone disease, and has a profound impact on quality of life. Therefore, effective pain relief is an important goal in managing metastatic bone disease. Orthopedic surgeons are often challenged with patients presenting with newly diagnosed bone metastases and severe and disabling bone pain. It is important to provide fast and sufficient analgesia. Clinical trials have demonstrated that bisphosphonates reduce effectively and sustained bone pain by approved standard dosage over time. Open label prospective trials have shown that short time high dose i.v. Ibandronate is effective in rapid pain relief in different primary tumors. Patients and methods: In 33 patients with metastatic bone pain from newly diagnosed skeletal metastases we utilized the loading-dose concept for intravenous ibandronate (6 mg infused over 1 h on 3 consecutive days). Results: In 33 patients loading-dose ibandronate therapy significantly reduced bone pain within the first 5?7 days (VAS day 0: 6?8 vs. day 7: 3?4). Only 3 patients showed no response concerning a distinct pain reduction within the first days of therapy. There was no increase in pain medication. Conclusion: This clinical observational study in selected patients with severe metastatic bone pain undergoing an intensive high dosed ibandronate-therapy for a short period demonstrated that loading-dose ibandronate (6 mg i.v., 3 consecutive days) resulted in a reduction of pain within days. Twit Text FOAVip Ibandronate: The loading dose concept in the treatment of metastatic bone pain ????J Bone Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26998420 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26998420 #FOAvip English Wikipedia <ref>{{Cite pmid|26998420}}</ref> Ibandronate: The loading dose concept in the treatment of metastatic bone pain #MMPMID26998420 Maier GS; Eberhardt C; Kurth AA J Bone Oncol 2016[Mar]; 5 (1): 1-4 PMID26998420show ga Background/Aim: Severe bone pain is experienced by 60?80% of patients with metastatic bone disease, and has a profound impact on quality of life. Therefore, effective pain relief is an important goal in managing metastatic bone disease. Orthopedic surgeons are often challenged with patients presenting with newly diagnosed bone metastases and severe and disabling bone pain. It is important to provide fast and sufficient analgesia. Clinical trials have demonstrated that bisphosphonates reduce effectively and sustained bone pain by approved standard dosage over time. Open label prospective trials have shown that short time high dose i.v. Ibandronate is effective in rapid pain relief in different primary tumors. Patients and methods: In 33 patients with metastatic bone pain from newly diagnosed skeletal metastases we utilized the loading-dose concept for intravenous ibandronate (6 mg infused over 1 h on 3 consecutive days). Results: In 33 patients loading-dose ibandronate therapy significantly reduced bone pain within the first 5?7 days (VAS day 0: 6?8 vs. day 7: 3?4). Only 3 patients showed no response concerning a distinct pain reduction within the first days of therapy. There was no increase in pain medication. Conclusion: This clinical observational study in selected patients with severe metastatic bone pain undergoing an intensive high dosed ibandronate-therapy for a short period demonstrated that loading-dose ibandronate (6 mg i.v., 3 consecutive days) resulted in a reduction of pain within days. äIbandronate: The loading dose concept in the treatment of metastatic b(epmc).pdf DeepDyve Pubget Overpricing